131 related articles for article (PubMed ID: 28819417)
1.
Deben C; Op de Beeck K; Van den Bossche J; Jacobs J; Lardon F; Wouters A; Peeters M; Van Camp G; Rolfo C; Deschoolmeester V; Pauwels P
J Cancer; 2017; 8(12):2154-2162. PubMed ID: 28819417
[No Abstract] [Full Text] [Related]
2. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
3. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
5. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
[TBL] [Abstract][Full Text] [Related]
6. MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.
Ryan BM; Calhoun KM; Pine SR; Bowman ED; Robles AI; Ambs S; Harris CC
Int J Cancer; 2012 Dec; 131(11):2710-6. PubMed ID: 22487911
[TBL] [Abstract][Full Text] [Related]
7. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
[TBL] [Abstract][Full Text] [Related]
8. Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).
Knappskog S; Gansmo LB; Dibirova K; Metspalu A; Cybulski C; Peterlongo P; Aaltonen L; Vatten L; Romundstad P; Hveem K; Devilee P; Evans GD; Lin D; Van Camp G; Manolopoulos VG; Osorio A; Milani L; Ozcelik T; Zalloua P; Mouzaya F; Bliznetz E; Balanovska E; Pocheshkova E; Kučinskas V; Atramentova L; Nymadawa P; Titov K; Lavryashina M; Yusupov Y; Bogdanova N; Koshel S; Zamora J; Wedge DC; Charlesworth D; Dörk T; Balanovsky O; Lønning PE
Oncotarget; 2014 Sep; 5(18):8223-34. PubMed ID: 25327560
[TBL] [Abstract][Full Text] [Related]
9. Specific allelic variants of SNPs in the
Bauer M; Kantelhardt EJ; Stiewe T; Nist A; Mernberger M; Politt K; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Buchmann J; Weigert E; Bürrig KF; Wickenhauser C; Thomssen C; Bartel F; Vetter M
Oncotarget; 2019 Mar; 10(20):1975-1992. PubMed ID: 30956778
[TBL] [Abstract][Full Text] [Related]
10. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.
Knappskog S; Lønning PE
Oncotarget; 2011 Mar; 2(3):251-8. PubMed ID: 21436469
[TBL] [Abstract][Full Text] [Related]
11. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.
Ortiz GJ; Li Y; Post SM; Pant V; Xiong S; Larsson CA; El-Naggar AK; Johnson DG; Lozano G
Oncogene; 2018 Jan; 37(3):332-340. PubMed ID: 28925402
[TBL] [Abstract][Full Text] [Related]
12. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
13. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
14. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
16. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
[TBL] [Abstract][Full Text] [Related]
18. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
19. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Knappskog S; Bjørnslett M; Myklebust LM; Huijts PE; Vreeswijk MP; Edvardsen H; Guo Y; Zhang X; Yang M; Ylisaukko-Oja SK; Alhopuro P; Arola J; Tollenaar RA; van Asperen CJ; Seynaeve C; Staalesen V; Chrisanthar R; Løkkevik E; Salvesen HB; Evans DG; Newman WG; Lin D; Aaltonen LA; Børresen-Dale AL; Tell GS; Stoltenberg C; Romundstad P; Hveem K; Lillehaug JR; Vatten L; Devilee P; Dørum A; Lønning PE
Cancer Cell; 2011 Feb; 19(2):273-82. PubMed ID: 21316605
[TBL] [Abstract][Full Text] [Related]
20. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
